PT2131813E - Formulação farmacêutica tópica - Google Patents

Formulação farmacêutica tópica Download PDF

Info

Publication number
PT2131813E
PT2131813E PT08709428T PT08709428T PT2131813E PT 2131813 E PT2131813 E PT 2131813E PT 08709428 T PT08709428 T PT 08709428T PT 08709428 T PT08709428 T PT 08709428T PT 2131813 E PT2131813 E PT 2131813E
Authority
PT
Portugal
Prior art keywords
composition according
diclofenac
glycol ether
ester
weight
Prior art date
Application number
PT08709428T
Other languages
English (en)
Portuguese (pt)
Inventor
Adrian Francis Davis
Original Assignee
Futura Medical Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Futura Medical Dev Ltd filed Critical Futura Medical Dev Ltd
Publication of PT2131813E publication Critical patent/PT2131813E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT08709428T 2007-03-13 2008-02-15 Formulação farmacêutica tópica PT2131813E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0704846.5A GB0704846D0 (en) 2007-03-13 2007-03-13 Topical pharmaceutical formulation

Publications (1)

Publication Number Publication Date
PT2131813E true PT2131813E (pt) 2012-10-31

Family

ID=37988913

Family Applications (1)

Application Number Title Priority Date Filing Date
PT08709428T PT2131813E (pt) 2007-03-13 2008-02-15 Formulação farmacêutica tópica

Country Status (21)

Country Link
US (1) US8541470B2 (enExample)
EP (2) EP2452671A2 (enExample)
JP (1) JP2010521442A (enExample)
CN (1) CN101663022A (enExample)
AU (1) AU2008224735B2 (enExample)
BR (1) BRPI0808887A2 (enExample)
CA (1) CA2680074C (enExample)
CO (1) CO6220926A2 (enExample)
DK (1) DK2131813T3 (enExample)
ES (1) ES2391914T3 (enExample)
GB (1) GB0704846D0 (enExample)
MX (1) MX2009009758A (enExample)
MY (1) MY149545A (enExample)
NZ (1) NZ579895A (enExample)
PL (1) PL2131813T3 (enExample)
PT (1) PT2131813E (enExample)
RU (1) RU2468794C2 (enExample)
SG (1) SG179480A1 (enExample)
TW (1) TWI367110B (enExample)
UA (1) UA100509C2 (enExample)
WO (1) WO2008110741A2 (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3300721B2 (en) * 2003-11-20 2025-01-08 Novo Nordisk A/S Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
SG10201703086VA (en) 2008-10-17 2017-05-30 Xenon Pharmaceuticals Inc Spiro-oxindole compounds and their use as therapeutic agents
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
JP5752136B2 (ja) 2009-10-14 2015-07-22 ゼノン・ファーマシューティカルズ・インコーポレイテッドＸｅｎｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． スピロ−オキシインドール化合物のための合成方法
CN105726531A (zh) 2010-02-26 2016-07-06 泽农医药公司 用于局部给药的螺-羟吲哚化合物的药物组合物及其作为治疗剂的用途
US11730709B2 (en) 2010-10-29 2023-08-22 Infirst Healthcare Limited Compositions and methods for treating severe pain
US10695432B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US9504664B2 (en) 2010-10-29 2016-11-29 Infirst Healthcare Limited Compositions and methods for treating severe pain
US8895537B2 (en) 2010-10-29 2014-11-25 Infirst Healthcare Ltd. Compositions and methods for treating cardiovascular diseases
US11202831B2 (en) 2010-10-29 2021-12-21 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US9308213B2 (en) 2010-10-29 2016-04-12 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US11224659B2 (en) 2010-10-29 2022-01-18 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US9271950B2 (en) 2010-10-29 2016-03-01 Infirst Healthcare Limited Compositions for treating chronic inflammation and inflammatory diseases
US9744132B2 (en) 2010-10-29 2017-08-29 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US9737500B2 (en) 2010-10-29 2017-08-22 Infirst Healthcare Limited Compositions and methods for treating severe pain
US10695431B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
AU2013246485A1 (en) 2012-04-12 2014-10-16 Xenon Pharmaceuticals Inc. Asymmetric syntheses for spiro-oxindole compounds useful as therapeutic agents
PL3795141T3 (pl) * 2013-01-14 2025-11-12 Infirst Healthcare Limited Kompozycje w postaci roztworu stałego
EP2943183A1 (en) * 2013-01-14 2015-11-18 InFirst Healthcare Limited Compositions and methods for treating severe pain
HK1218621A1 (zh) * 2013-02-04 2017-03-03 Infirst Healthcare Limited 用於治疗慢性炎症和炎性疾病的组合物及方法
US9012402B1 (en) 2014-06-11 2015-04-21 James Blanchard Gel for topical delivery of NSAIDs to provide relief of musculoskeletal pain and methods for its preparation
US11007161B1 (en) 2014-12-31 2021-05-18 Eric Morrison Ibuprofen nanoparticle carriers encapsulated with hermatic surfactant films
US10561627B2 (en) 2014-12-31 2020-02-18 Eric Morrison Ibuprofen nanoparticle carriers encapsulated with hermetic surfactant films
US10596117B1 (en) 2014-12-31 2020-03-24 Eric Morrison Lipoleosomes as carriers for aromatic amide anesthetic compounds
TW201636017A (zh) 2015-02-05 2016-10-16 梯瓦製藥國際有限責任公司 以螺吲哚酮化合物之局部調配物治療帶狀疱疹後遺神經痛之方法
GB201502845D0 (en) * 2015-02-20 2015-04-08 Futura Medical Dev Ltd Topical pharmaceutical formulation
FR3041534B1 (fr) * 2015-09-30 2019-03-15 Vetoquinol Sa Composition de nettoyant auriculaire
GB201609968D0 (en) * 2016-06-07 2016-07-20 Futura Medical Dev Ltd Topical pharmaceutical formulation
US10100060B2 (en) 2016-06-16 2018-10-16 Xenon Pharmaceuticals Inc. Asymmetric synthesis of funapide
WO2018163176A1 (en) * 2017-03-07 2018-09-13 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Topical delivery systems for active compounds
US10821075B1 (en) 2017-07-12 2020-11-03 James Blanchard Compositions for topical application of a medicaments onto a mammalian body surface
CN118903386A (zh) 2017-08-24 2024-11-08 诺和诺德股份有限公司 Glp-1组合物及其用途
KR20220143036A (ko) 2020-02-18 2022-10-24 노보 노르디스크 에이/에스 약학적 제형
GB2596286B (en) 2020-06-20 2023-01-25 Francis Davis Adrian Adherence to topical therapy
EP4188325A1 (en) 2020-07-27 2023-06-07 Incanthera R&D Ltd. Topical formulation
GB2597526A (en) 2020-07-27 2022-02-02 Incanthera R&D Ltd Topical formulation
GB202012836D0 (en) 2020-08-17 2020-09-30 Futura Medical Developments Ltd Topical composition

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06104624B2 (ja) * 1986-05-07 1994-12-21 太郎 小木曽 経皮吸収剤
PE20011092A1 (es) 2000-02-14 2001-11-12 Procter & Gamble Composiciones para el suministro topico de un agente farmaceuticamente activo que tiene reducida irritacion de la piel
DE10019171A1 (de) * 2000-04-07 2001-10-18 Schering Ag Zusammensetzungen zur Verwendung als Penetrationsverstärker in transdermalen Formulierungen für hoch lipophile Wirkstoffe
PE20040321A1 (es) * 2002-08-22 2004-07-15 Novartis Consumer Health Sa Composicion topica que comprende diclofenaco
US7132452B2 (en) * 2003-03-10 2006-11-07 Fang-Yu Lee Topical formulation having effects on alleviating pain/inflammation caused by herpes virus infection
US20050137164A1 (en) * 2003-09-22 2005-06-23 Moshe Arkin Diclofenac compositions for the treatment of skin disorders
EP1588697A1 (en) 2004-04-16 2005-10-26 Kurt H. Prof. Dr. Bauer Emulsion gel for topical application of pharmaceuticals
US20050244522A1 (en) 2004-04-30 2005-11-03 Carrara Dario Norberto R Permeation enhancer comprising genus Curcuma or germacrone for transdermal and topical administration of active agents

Also Published As

Publication number Publication date
GB0704846D0 (en) 2007-04-18
DK2131813T3 (da) 2012-10-29
WO2008110741A8 (en) 2009-11-19
PL2131813T3 (pl) 2012-11-30
NZ579895A (en) 2012-02-24
CA2680074A1 (en) 2008-09-18
TWI367110B (en) 2012-07-01
WO2008110741A2 (en) 2008-09-18
MX2009009758A (es) 2009-09-24
WO2008110741A3 (en) 2009-03-12
US20100099767A1 (en) 2010-04-22
RU2009136228A (ru) 2011-04-20
RU2468794C2 (ru) 2012-12-10
AU2008224735B2 (en) 2013-04-18
UA100509C2 (ru) 2013-01-10
AU2008224735A1 (en) 2008-09-18
EP2131813A2 (en) 2009-12-16
TW200836769A (en) 2008-09-16
JP2010521442A (ja) 2010-06-24
SG179480A1 (en) 2012-04-27
EP2131813B1 (en) 2012-08-08
CA2680074C (en) 2016-07-12
ES2391914T3 (es) 2012-12-03
MY149545A (en) 2013-09-13
CN101663022A (zh) 2010-03-03
EP2452671A2 (en) 2012-05-16
US8541470B2 (en) 2013-09-24
BRPI0808887A2 (pt) 2014-09-02
CO6220926A2 (es) 2010-11-19

Similar Documents

Publication Publication Date Title
PT2131813E (pt) Formulação farmacêutica tópica
CA2748346C (en) Use of a foamable composition essentially free of pharmaceutically active ingredients for the treatment of human skin
ES2263182T3 (es) Composicion adecuada para el tratamiento de laminitis equina.
RU2754846C1 (ru) Обезболивающие композиции местного действия
CN106572970B (zh) 用于局部给药非甾体抗炎药以缓解肌肉骨骼疼痛的新型凝胶及其制备方法
BR112020024768A2 (pt) Método para reduzir o intervalo de penetração cutânea de roflumilaste em um paciente, composição farmacêutica compreendendo roflumilaste e uma mistura emulsificante e composição farmacêutica compreendendo roflumilaste e pelo menos um emulsificante
PT503988E (pt) Composicoes para o tratamento de onicomicoses
ES2691299T3 (es) Composiciones tópicas, que contienen un retinoide, de tipo emulsión de aceite en agua
ES2590258T3 (es) Preparación antiinflamatoria y analgésica para uso externo
JP5052558B2 (ja) ゲル軟膏
US10028927B2 (en) Topical pharmaceutical formulation
HU226122B1 (en) Pharmaceutical composition in gel form for topical use containing nimesulide and process for preparation thereof
WO2017109761A1 (en) Topical composition for the treatment of acne
US11376213B2 (en) Topical pharmaceutical formulation
JP2003012501A (ja) 鎮痒エアゾール製剤
JP2024507011A (ja) エマルション組成物、ならびに放射線によって引き起こされる皮膚損傷の予防および／または処置におけるその使用
CA2500907A1 (en) Vehicle for topical delivery of anti-inflammatory compounds
HK1170676A (en) Topical pharmaceutical formulation
BR102017011377B1 (pt) Composição e formulação tópica anestésica de (2e,8e)- n-isobutildeca- 2,8-dien-6-inamida e seu uso
EA018384B1 (ru) Композиция дигидрата 3-(2,2,2-триметилгидразиниум) пропионата для наружного местного применения
HK1140954A (zh) 局部药物制剂
WO2022178604A1 (pt) Composição farmacêutica tópica espumável
TR2024002454A1 (tr) Topical compositions comprising nimesulide and diclofenac sodium and a salicylate
TR201720497A2 (tr) Adapalen, benzoi̇l peroksi̇t ve si̇katri̇zan grubundan bi̇r ajan i̇çeren kombi̇nasyon